Pasithea Therapeutics Corp. (KTTA) Earnings History
Annual and quarterly earnings data from 2020 to 2024
Loading earnings history...
KTTA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
KTTA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | -14.7% | -29925.7% | -14430.5% |
| 2020 | - | - | - |
Download Data
Export KTTA earnings history in CSV or JSON format
Free sign-in required to download data
Pasithea Therapeutics Corp. (KTTA) Earnings Overview
As of May 8, 2026, Pasithea Therapeutics Corp. (KTTA) reported trailing twelve-month net income of -$13M, reflecting +2.5% year-over-year growth. The company earned $-1.81 per diluted share over the past four quarters.
Looking at the long-term picture, KTTA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$61,476 in fiscal 2020.
Pasithea Therapeutics Corp. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CMPS (-$288M net income), ATAI (-$154M net income, -48464.0% margin), MNMD (-$238M net income), KTTA has comparable earnings metrics. Compare KTTA vs CMPS →
KTTA Earnings vs Peers
Earnings metrics vs comparable public companies
KTTA Historical Earnings Data (2020–2024)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$14M | +12.9% | -$14M | $-12.69 | - | - |
| 2023 | -$16M | -14.5% | -$16M | $-13.01 | - | - |
| 2022 | -$14M | -541.2% | -$13M | $-10.34 | - | - |
| 2021 | -$2M | -3435.6% | -$5M | $-1.89 | -14430.5% | -29925.7% |
| 2020 | $-61,476 | - | $-61,476 | $-0.06 | - | - |
See KTTA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KTTA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KTTA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKTTA — Frequently Asked Questions
Quick answers to the most common questions about buying KTTA stock.
Is KTTA growing earnings?
KTTA EPS of $-1.81 reflects slowing growth at +2.5%, below the 5-year CAGR of N/A. TTM net income is $-13M. Expansion rate has moderated.
What are KTTA's profit margins?
Pasithea Therapeutics Corp. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are KTTA's earnings?
KTTA earnings data spans 2020-2024. The current earnings trend is +2.5% YoY. Historical data enables comparison across business cycles.